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Neuroimaging research has substantiated the functional and structural abnormalities 
underlying psychiatric disorders but has, thus far, failed to have a significant impact on 
clinical practice. Recently, neuroimaging-based diagnoses and clinical predictions derived 
from machine learning analysis have shown significant potential for clinical translation. 
This review introduces the key concepts of this approach, including how the multivariate 
integration of patterns of brain abnormalities is a crucial component. We survey recent 
findings that have potential application for diagnosis, in particular early and differential 
diagnoses in Alzheimer disease and schizophrenia, and the prediction of clinical response 
to treatment in depression. We discuss the specific clinical opportunities and the challenges 
for developing biomarkers for psychiatry in the absence of a diagnostic gold standard. We 
propose that longitudinal outcomes, such as early diagnosis and prediction of treatment 
response, offer definite opportunities for progress. We propose that efforts should be 
directed toward clinically challenging predictions in which neuroimaging may have added 
value, compared with the existing standard assessment. We conclude that diagnostic and 
prognostic biomarkers will be developed through the joint application of expert psychiatric 
knowledge in addition to advanced methods of analysis.
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Biomarqueurs de neuroimagerie en psychiatrie :  
possibilités cliniques d’un changement de paradigme
La recherche en neuroimagerie a fourni la preuve des anomalies fonctionnelles et 
structurelles sous-jacentes des troubles psychiatriques, mais jusqu’ici, elle n’a pas réussi à 
avoir un impact significatif sur la pratique clinique. Récemment, les diagnostics basés sur la 
neuroimagerie et les prédictions cliniques tirées d’une analyse d’apprentissage automatique 
ont démontré un potentiel significatif de traduction clinique. Cette revue présente les 
concepts clés de cette approche, notamment à quel point l’intégration multivariée des 
modèles d’anomalies cérébrales est un composant essentiel. Nous passons en revue les 
résultats récents qui ont des applications potentielles au diagnostic, en particulier, pour 
les diagnostics précoces et différentiels de la maladie d’Alzheimer et de la schizophrénie, 
et la prédiction de la réponse clinique au traitement de la dépression. Nous discutons des 
possibilités cliniques spécifiques et des défis de développement de biomarqueurs pour 
la psychiatrie en l’absence de standard de référence diagnostique. Nous proposons que 
les résultats longitudinaux, comme le diagnostic précoce et la prédiction de la réponse au 
traitement, offrent des possibilités définitives de progrès. Nous proposons que des efforts 
soient dirigés vers des prédictions cliniquement difficiles dans lesquelles la neuroimagerie 
peut avoir une valeur ajoutée, comparée à l’évaluation standard existante. Nous concluons 
que les biomarqueurs diagnostiques et pronostiques seront développés par l’application 
conjointe du savoir psychiatrique expert et de méthodes d’analyse avancées. 
A biomarker is “a characteristic that is objectively measured and evaluated as an indicator of normal 
biologic processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention.”1, p 91 Biomarkers are 
key components of modern medicine; for example, blood 
glucose monitoring is the cornerstone for the diagnosis and 
clinical management of diabetes. Nevertheless, decisions 
for psychiatric disorders are almost entirely based on 
inferences on self-reported information and the observation 
of behaviour. Therefore, clinical decisions rely on a patient’s 
ability to collaborate as well as the expertise and experience 
of the clinician. The resulting potential for ambiguity and 
bias can result in low reliability for psychiatric diagnoses.2 
Moreover, a diagnosis based on clinical description may 
not map with etiology and prognosis,3 which may, in turn, 
impact negatively on treatment decisions.
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Abbreviations
AD antidepressant
BD bipolar disorder
MCI mild cognitive impairment
MDD major depressive disorder
MRI magnetic resonance imaging
SVM support vector machine
Highlights
• The development of neurobiological diagnostic markers 
will require an iterative process, while pursuing higher 
levels of sensitivity and specificity to perfectly replicate 
current criteria-based diagnostic categories would be 
misguided.
• There is potential significant value in neuroimaging-
based prediction of clinical response to improve clinical 
outcome.
• Expert knowledge is crucial for the successful translation 
of these potential biomarkers to clinical practice.
Limitations
• There are no gold standard diagnostic markers in 
psychiatric disorders. Consequently, it would be 
misguided to aim for the highest sensitivity and 
specificity based on current diagnostic criteria.
It is no longer disputable that psychiatric disorders are 
brain disorders associated with abnormalities in distributed 
networks.4 Neuroimaging provides in vivo access to these 
abnormal brain circuits, and systematic differences have 
been observed between healthy people and patients with 
psychiatric disorders in brain structure, function, and 
neurochemistry. Brain imaging has substantially increased 
our knowledge of the pathophysiology of mental illnesses 
and is a candidate for the development of clinical diagnostic 
biomarkers. In particular, the potential of neuroimaging-
based biomarkers lies not only in diagnosis but also 
for prognosis. Though clinical features may provide an 
indication of how well a patient’s illness may respond to 
a particular treatment, biomarkers for predicting clinical 
response are not currently used in day-to-day practice. A 
prognostic biomarker could point toward the initiation of 
more intensive or combined therapies at an earlier stage 
in patients who have an illness that has been identified as 
being more difficult to treat, thus reducing the morbidity 
associated with potentially multiple, poorly effective 
treatments.
The Development of Neuroimaging-Based 
Biomarkers
Our review focuses on the key markers needed in clinical 
applications: diagnosis and prognosis. We review the 
research studies that have demonstrated neuroimaging-
based markers that have the potential for clinical translation. 
These neuroimaging studies can be broadly grouped into 
measures of brain structure or brain function. Structural 
measures include regional brain volumes and measures 
of white matter, and functional neuroimaging data range 
from resting-state measures to task-related activation 
studies. Both structural and functional neuroimaging 
data can be derived from the brain, as a whole or from 
specified individual regions. Which neuroimaging 
measure, combination of neuroimaging measures, or even 
combination of neuroimaging and clinical measures will 
provide the best diagnostic and prognostic biomarkers 
remains an open empirical question. Our review also 
examines how biomarkers for early and differential 
diagnostics can be developed, as well as markers that go 
beyond the usual categorical yes-or-no decision but can 
offer the probability associated with a particular prediction. 
We contend that it is by focusing on diagnosis and prognosis 
that neuroimaging-based biomarkers are more likely to offer 
added value, compared with the existing clinical assessment. 
We also review the specific challenges of validating new 
neuroimaging-based biomarkers for psychiatric conditions 
as current diagnostic criteria suffer from limited reliability 
and may be dissociated from neurobiological abnormalities. 
We propose that the joint application of expert psychiatric 
knowledge and advanced analytic methods is essential 
for the development of these much-needed clinical tools. 
Finally, we discuss the next steps required to maximize the 
impact of this approach for research and clinical practice.
From Neuroimaging Findings to Clinical 
Applications
The conventional output from a neuroimaging study is 
a brain map, which summarizes measures from many 
subjects. In psychiatry, a typical study reports the significant 
differences in regional brain responses or structure between 
a given sample of patients and healthy control subjects. 
These group-level findings aim to identify the functional 
and structural brain phenotypes associated with a given 
disorder. To develop clinical tools, the investigation requires 
a shift away from considering differences at the group level, 
such as between patients and control subjects. Instead, the 
question becomes whether the brain map of a given person 
is expressing the neural phenotype for a specific disorder 
or clinical outcome. In other words, the aim is to use brain 
measurements for the prediction at the individual level 
regarding diagnosis—whether a given subject is ill or 
healthy—and prognosis—whether a given patient will show 
a good or poor clinical response to a particular treatment.
However, a fundamental difficulty is the inherent complexity 
of brain images that are 3-dimensional arrays of data 
constituted by a high number of localized measurements 
(known as its volumetric elements or voxels, for short). 
Genetics, functional genomics, and proteomics similarly 
generate detailed, highly dimensional measurements that 
contain clinically valuable predictive information. All of 
these fields share similar analytical challenges,5 as classical 
statistical methods generally require more observations 
(subjects) than input variables (for example, voxels or 
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genes). Instead, neuroimaging studies typically involve 
samples sizes in the order of tens to hundreds of subjects 
consisting of thousands to millions of voxels per subject.
Machine learning is a collection of methods derived from 
artificial intelligence and statistical learning. These methods 
have been a key facilitator in developing biomarkers 
from brain-imaging data as they have proven effective at 
tackling the analytic challenges of high-dimensional data.5–7 
Such methods have already led to practical commercial 
applications, for example, face and speech recognition8 
and clinical prediction based on genomic information.5 In 
neuroimaging, machine learning methods underpin recent 
advances in so-called mind-reading, whereby thoughts and 
intentions are identified from the pattern of brain activation 
alone.9
An important feature of machine learning algorithms is 
that they are designed to deal with multivariate inputs; in 
other words, they treat the brain images as patterns rather 
than considering each voxel in isolation as in conventional 
analysis methods. Multivariate approaches allow the 
integration over the whole brain of localized differences, 
which individually may be too small in magnitude or too 
variable to reliably separate groups of subjects (Figure 1). 
As neuroimaging studies in psychiatric disorders tend to 
reveal abnormalities that affect a network of regions rather 
than isolated, localized changes,10 the multivariate approach 
is able to integrate such patterns of differences leading to 
improvements in predictive accuracy.
The steps in the analysis involve teaching the machine 
learning algorithms to recognize samples of brain images, 
such as patients and control subjects (Figure 2). The 
algorithm learns the characteristics in these patterns 
associated with either group. In other words, the algorithm 
learns the phenotype associated with the characteristic to be 
predicted, be it diagnostic or prognostic. Once the algorithm 
has been trained, this knowledge can be applied to novel 
scans, resulting in subject-specific clinical predictions. 
For instance, the novel brain image is then classified as 
belonging to one group or the other, such as patients or 
control subjects. Further technical details have been recently 
reviewed.11,12 Moreover, it is possible to combine different 
types of data, such as neuroimaging with clinical measures, 
which may improve the accuracy of the prediction.
Diagnosis, Early Diagnosis, and Differential 
Diagnosis
The strongest potential for clinical application to date has 
been in Alzheimer disease, owing to its well-characterized 
brain atrophy, which begins in the medial temporal lobe and 
spreads to neocortical regions.13–15 This atrophic phenotype 
of Alzheimer disease has been replicated by machine 
learning analyses.16–18 Using cases of Alzheimer disease 
that have been verified by postmortem investigation, 
high diagnostic accuracy of individual patients has been 
achieved, with a sensitivity of 95% and specificity of 95%, 
while expert neuroradiologists achieved only a sensitivity 
of 88% and specificity of 90% for the same dataset.19,20 
Measures of white matter with diffusion tensor imaging 
have reported a diagnostic accuracy of 98%.21
The clinical diagnosis of Alzheimer disease is made when 
marked and progressive cognitive impairments are already 
evident. A diagnosis, though, would be more useful at an 
earlier stage, while the patient is experiencing few cognitive 
deficits, such as in the form of self-reported memory loss. 
Figure 1  Improving classification with multivariate methods
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This hypothetical classification problem illustrates how multivariate integration can improve accuracy. 
This example aims to separate 2 groups of subjects (green circles representing depressed patients, blue 
diamonds as healthy control subjects) based on 2 quantitative neuroimaging measurements (anterior 
cingulate and amygdala activation). In practice, multivariate integration generally involves more than 2 
variables, but the principles illustrated here still apply. None of the 2 features can, in isolation, accurately 
separate the 2 groups. However, the integration of both measurements using a multivariate linear 
classification boundary achieves high separation.
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However, currently it is impossible to predict from clinical 
and neuropsychological testing whether an individual with 
mild cognitive deficits will subsequently progress toward 
dementia or will remain stable.22 Analysis of brain images of 
people with MCI has the potential to aid with this diagnostic 
transition.23–25 Indeed, the development of Alzheimer disease 
was predicted at an accuracy of 80% from the pattern of 
changes in hippocampal morphology (n = 30 MCI subjects: 
sensitivity 80%, specificity 80%),23 which was validated in 
a large-scale, multicentre trial at the same level of accuracy 
(n = 103 MCI subjects: sensitivity 77%, specificity 80%).24 
Importantly, MCI subjects who developed dementia could 
not have been distinguished at baseline based on clinical, 
demographic, and neuropsychological features, providing 
evidence that the neuroimaging-based prediction could add 
value to the standard diagnostic assessment.
The differential diagnosis of Alzheimer disease from 
other degenerative dementias also presents as a clinical 
challenge. Further, the degree of overall brain atrophy may 
not distinguish between pathologies,26 instead it may be the 
pattern of atrophy that is useful for diagnostic classification. 
In Alzheimer disease, the medial temporal cortex is more 
specifically affected than in non-Alzheimer pathologies, 
such as dementia with Lewy bodies and vascular cognitive 
impairment.27 A recent 3-way diagnosis has been applied 
to structural MRI scans of pathologically verified cases of 
dementia.28 High accuracy of diagnosis was found for all 
diagnoses: Alzheimer disease (sensitivity 91%, specificity 
84%), Lewy body disease (sensitivity 79%, specificity 
99%), and frontotemporal degeneration (sensitivity 84%, 
specificity 94%).
Functional imaging information has also shown diagnostic 
potential. Brain activation during language and memory 
tasks measured by functional MRI distinguishes Alzheimer 
patients and healthy control  subjects with over 80% 
sensitivity and specificity.29,30 Classification using resting-
state perfusion by single photon emission computed 
tomography (commonly referred to as SPECT)31,32 also 
generated high diagnostic performance (sensitivity 90%, 
specificity 70%), surpassing the accuracy of a panel of 
expert neuroradiologists (sensitivity 57%, specificity 82%). 
Whether functional and structural abnormalities contain 
distinct diagnostic patterns and can be used for improved 
clinical performance or whether they express similar and 
redundant information is an important question to be further 
explored. Structural MRI has an advantage of already being 
Figure 2  Training and testing of classification models
The phenotype associated with an outcome of interest (in this example, subjects diagnosed with MDD and healthy control subjects) is 
first learned using the scans of well-characterized people. The trained model is then used to generate predictions based on the scans 
of new, undiagnosed subjects. The trained model is usually represented by a map depicting the regional abnormalities associated 
with the prediction most important for classification.
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routinely used in the assessment of suspected dementia.33 
Therefore, machine learning analysis can be seen as an add-
on tool to the usual neuroradiological examination, which 
has the potential to lead to improved early diagnosis of 
Alzheimer disease and its differential diagnosis.
MDD is characterized by structural and functional brain 
abnormalities involving limbic and prefrontal regions.34,35 
Using machine learning analysis, we have shown that the 
functional correlates of implicitly processing emotional faces 
is diagnostic for depression (sensitivity 84%, specificity 
89%).36 While the functional neuroanatomy of verbal 
working memory also shows distinct neural correlates in 
MDD37 and generated a statistically significant diagnostic 
accuracy for depression (sensitivity 65%, specificity 
70%),38 the clinical significance is limited, owing to its low 
accuracy. Additional sensitivity though may be generated 
by combining functional imaging tasks of emotional and 
reward processing.39 Structural abnormalities are evident 
in depression, in particular in the hippocampus, which 
is present in the first episode40; however, these provided 
statistically significant but clinically limited diagnostic 
potential (sensitivity 65%, specificity 70%) for patients with 
a moderate severity of depression.40 The diagnostic accuracy 
of structural neuroimaging data, though, may be greater in 
patients who experience a more severe form of the illness.41
In schizophrenia, structural MRI has also shown diagnostic 
potential in identifying patients relative to healthy control 
subjects, using both whole brain images42,43 and hippocampal 
abnormalities.42–45 However, these studies have generally 
focused on patients with well-established schizophrenia. 
Once more, accurate diagnosis of schizophrenia at the early 
stages is a significant clinical challenge.46 Characteristic 
structural brain abnormalities have been identified in people 
with high levels of schizotypy and prodromal symptoms of 
psychosis, which have been applied to predict the risk of 
transition to a psychotic episode.47,48 As well, the differential 
diagnosis raises another clinical concern. Distinguishing 
people with schizophrenia from those with BD and healthy 
control subjects has been achieved with a sensitivity and 
specificity of over 90% based on functional abnormalities 
in prefrontal and temporal cortices and within default 
neural networks.49–51
Neuroimaging-based prediction has also shown promising 
results in classifying subjects with obsessive–compulsive 
disorder,52 autism spectrum disorders,53 BD,46,54 and 
substance abuse.55 Most of these studies have found 
abnormalities that were regionally distributed but of 
relatively small magnitudes, and therefore with much 
overlap between patients and control subjects for any given 
region, which machine learning approaches were able to 
integrate leading to accurate classification.
Predicting Clinical Response to Treatment
Treatment response prediction in depression is a clinical 
concern in which prognostic biomarkers could have a 
significant impact. Current treatment decisions are made on a 
trial-and-error basis, with little, if any, empirically validated 
guidance for which treatment is likely to be most effective for 
a particular person. Initial reports of an association of anterior 
cingulate function with treatment response to ADs56,57 have 
been replicated and extended in neuroimaging treatment 
studies of pharmacotherapy58 and psychological therapy,59 
with evidence of involvement of areas beyond the anterior 
cingulate.60 As well, we have observed distinct predictors 
of clinical response to pharmacotherapy, compared with 
psychological treatment. The structural neuroanatomy 
of depression was highly predictive treatment response 
to ADs,40,61 while it was the pattern of functional neural 
responses to emotional processing that predicted clinical 
response to cognitive-behavioural therapy.62 Functional 
neural correlates of emotional processing or verbal memory 
showed statistically significant but clinically limited 
predictive potential for ADs.36,38 The neural substrate for 
such predictions was consistent with regions implicated in 
depression, such as in the amygdala and anterior cingulate.56–58 
These findings suggest that a combination of both structural 
and functional imaging tests may lead to a useful aid in the 
clinical management of depression, as well as schizophrenia63 
and other disorders.
Integration With Expert Knowledge I: 
Defining Clinically Important Targets  
for Prediction
Expert knowledge is crucial for the successful translation 
of these potential biomarkers to clinical practice. Clinical 
expertise is required to formulate useful questions for 
which neuroimaging could conceivably add value over 
the existing clinical assessment. For instance, identifying 
people with established dementia from healthy control 
subjects does not usually present as a clinical challenge 
with standard clinical assessments and therefore machine 
learning is unlikely to add value. However, when doubts 
exist concerning the etiology of a dementia syndrome, 
neuroimaging-based prediction can be useful for differential 
diagnosis.28 In the early diagnosis of Alzheimer disease, 
neuroimaging can help to identify the pattern of atrophy 
characteristic of this disorder, a role already accepted in 
recently proposed diagnostic criteria. Similarly, while well-
established schizophrenia is usually identifiable with a 
standard clinical assessment, the identification of people at 
risk who are more likely to develop a full-blown psychotic 
episode based on their neuroimaging phenotype may offer 
a real clinical advantage.48
A specific difficulty in the development of new biomarkers 
is the absence of a true diagnostic gold standard for 
psychiatric disorders. A gold standard should separate 
subjects with and without the condition with near-perfect 
accuracy.64 However, in psychiatry, diagnosis is based on 
the application of criteria to self-reported information and 
the observation of behaviour. The reliability of this strategy 
can be low for many diagnoses.2 More importantly, current 
diagnostic classification systems for psychiatry do not 
explicitly link to etiology, and it is unknown to what extent 
they capture the underlying biological basis.3
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In machine learning, successful algorithm training 
depends on the availability of a sample of subjects with 
the condition of interest, who are therefore likely to 
express the neurobiological abnormalities to be learned 
by the algorithm. Any subjects that have been erroneously 
classified will introduce unwanted variability in this 
training process, a blurring of the neurobiological features 
that will tend to make the resulting test less accurate. 
Diagnostic misclassification is particularly likely in early 
diagnosis, before the full clinical picture has appeared. For 
instance, heterogeneous categories of MCI or prodromal 
psychosis contain a significant proportion of subjects who 
do not express the biological markers of the process and 
will never develop the full condition. More critically, if the 
aim is to build a more valid diagnostic system rooted in core 
etiological and pathophysiological realities, then pursuing 
higher levels of sensitivity and specificity in an attempt 
to perfectly replicate current criteria-based diagnostic 
categories would be misguided.3,65 Further, using a flawed 
gold standard, such as criteria-based diagnosis to validate a 
potentially superior biologically-based marker, would yield 
misleading estimates of its performance.64
Instead, a successful training and validation strategy for 
new biomarkers has to consider the limitations in current 
diagnostic criteria. A general approach to overcome 
diagnostic misclassification is to train the model (that is, 
read the neurobiological abnormalities constituting the 
phenotype of interest) in subjects for which there is very 
little diagnostic uncertainty, for instance, because they 
have remained stable in a particular diagnostic category 
for some time. For early diagnosis, this involves training 
the algorithm in patients with an established diagnosis, 
for example, Alzheimer disease24 or schizophrenia. While 
in these subjects the test would have little or no clinical 
added value, their diagnostic homogeneity should result in 
a good-quality reading of the neurobiological abnormalities 
into the trained algorithm. This accurate test can then be 
applied to subjects for whom diagnostic doubts exist; 
for instance, because they are suspected to be at the very 
early stages of a disorder, looking for indications that their 
neuroimaging phenotype already shows similarities to that 
of more advanced patients.24 This approach is particularly 
suited to predicting clinically important outcomes in which 
early, prodromal neurobiological changes are suspected to 
precede the full clinical expression of the disorder. This 
procedure also has the advantage of conducting the training 
and testing procedure in entirely separate sets of patients, 
adding to its validity and the likelihood that the observed 
predictive performance of the test can be generalized to 
new patients in whom the condition is suspected.
Another strategy is to use neuroimaging to predict events 
that are relatively independent of diagnostic criteria but 
have intrinsic clinical value and can therefore act as 
external validators of clinical diagnoses.66,67 One example 
is the prediction of treatment response. In depression, the 
demonstration that remission can be predicted based on 
a brain scan before treatment initiation strongly suggests 
that neuroimaging is able to capture essential components 
of its biology.40,68 As well, the prediction of disease onset, 
such as using neuroimaging to predict whether someone 
experiencing memory loss is, in fact, in the early stages 
of dementia, not only of immediate clinical utility but also 
offers strong evidence for the validity of the underlying 
neurobiological abnormalities as diagnostic markers. 
Additionally, the prediction of prognosis and treatment 
response is particularly unsatisfactory in many areas of 
psychiatry, and the usual clinical assessment often does not 
reveal sufficient information to orient treatment decisions, 
which are therefore made on a trial-and-error basis. As the 
value of a new biomarker ultimately lies in their capacity to 
improve patient outcomes, neuroimaging-based prediction 
is thus likely to offer significant added value in this area.69
Integration With Expert Knowledge II: 
Defining What to Measure
Nevertheless, the role of neuroimaging-based biomarkers 
for the diagnosis of psychiatric disorders is not necessarily 
limited to replicating diagnostic criteria systems. We expect 
that there will be an iterative process, in which previous 
neuroimaging-based prediction results can generate new 
hypotheses and be incorporated as prior knowledge for 
future studies. Raw brain measurements are not usually 
employed to train the machine learning algorithms, but 
rather highly preprocessed data are used instead. In most 
applications, measurements from many brain regions may 
not be valuable for the prediction task. This redundant input 
should be discarded while identifying and focusing the 
learning process on the most promising features. Because 
these spurious features have no real discriminative power 
in the population, using such irrelevant voxels to develop a 
predictive model will compromise its capacity to generate 
accurate predictions for new subjects.6,70,71 If there is a 
known set of affected regions, the classifier can be focused 
on measurements from these regions of interest, while 
ignoring measurements from other regions.72 In Alzheimer 
disease, the preprocessing can thus involve segmentation 
of the brain regions known to suffer atrophy in the earlier 
stages of the illness, namely, in the hippocampus.73 
Therefore, selection of the appropriate imaging modality 
and preprocessing strategy is crucial for successful 
prediction as it reflects previous expert knowledge. In most 
disorders, though, the best modality, preprocessing strategy, 
and regions of interest are not fully known a priori. In these 
situations, prior knowledge can be combined with data-
driven selection of the most important input features.68
Next Steps
Machine learning applied to neuroimaging is a novel 
approach that has the capacity to generate biomarkers with 
clinical applicability. The examples have focused on the 
results most likely to translate into clinical tools, and they 
are likely to be only a small subset of the potential of this 
methodology. Whether a group-level difference in brain 
patterns translates into statistically significant but more 
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importantly a clinically relevant individual-level prediction 
is an empirical, testable hypothesis that should be addressed 
as a complement to conventional analysis.24,51 This inclusive 
approach to biomarker discovery in neuroimaging mirrors 
the strategies currently used in similar high-dimensional 
fields, such as genetics and -omics.5
To realize this translational potential, the potential 
biomarker needs to be taken from the discovery stage, 
to the development of standardized clinical assay, and to 
clinical implementation.74 The next step after discovery 
is to confirm the initial results in an external sample; that 
is, the demonstration that the biomarker generalizes and is 
also useful in other patients. The diagnostic value of medial 
temporal atrophy in Alzheimer disease has been well 
studied and is considered to be a confirmatory diagnostic 
criterion.74 In depression, the findings that functional 
abnormalities have diagnostic potential36 and the predictive 
potential of grey matter abnormalities40 has been confirmed 
in independent samples.39,61 Validation studies are essential 
and should include subjects representative of the population, 
compared with the so-called clean, comorbidity-free, clear-
cut patients who are normally used in proof-of-principle 
studies.73 Multicentre designs are particularly convincing, 
because they can test whether that the prediction is robust 
to differences in prevalence, recruitment, and clinical 
management.20,73
With standardization of acquisition methods and analysis,75 
the predictive models obtained with machine learning 
analysis in one study can be stored in a database and 
tested with different samples. A repository consisting of 
trained models that have shown predictive potential in 
one sample can be accessed by other researchers for test 
purposes and would accelerate progress. Well-documented, 
user-friendly, open-source machine learning toolboxes 
have been developed (for example, Princeton Multi-
Voxel Pattern Analysis toolbox [MVPA]76 and its Python 
version [PyMVPA]77), which can analyze most types of 
neuroimaging data using various approaches, and offer a 
relatively pain-free approach for clinical scientists to test 
the predictive value of their experiments.9 There are also 
numerous mathematical methods for pattern recognition 
that have proved their value when applied to neuroimaging. 
It remains an area of active inquiry in machine learning 
research whether specific algorithms work best for specific 
high-dimensional datasets. The predominant technique 
has been SVM classification.7,78 SVM finds an optimal 
boundary between groups by focusing not on the full 
sample, but only on those examples that are difficult to 
classify. This leads to good theoretical generalization 
properties even in high-dimensional classification problems, 
which have been empirically effective in different areas of 
medicine, including for the diagnosis of breast tumours in 
mammographies,79 and cancer diagnosis and prediction of 
response to chemotherapy using gene expression data,7,80,81 
in addition to neuroimaging. While some concerns have 
been raised that relatively long analysis time (currently in 
the order of days) may be an impediment to the practical 
application of neuroimaging-based diagnosis,12 we would 
assert that such concerns are overstated as this period is 
comparable to many other laboratory tests, while psychiatric 
emergencies can be continued to be treated as per current 
procedures.
An important step, though, is to go beyond dichotic 
prediction, such as patient compared with control subject, or 
responder compared with nonresponder. We have proposed 
a general probabilistic approach to neuroimaging-based 
classification, which produces accurate predictions along 
with a confidence level, the probability that the prediction 
is actually correct for that specific patient.68 Developments 
in pattern regression also allow the prediction of continuous 
variables,82 paralleling the dimensional outcomes 
commonly used in clinical psychiatry, such as rating or 
symptom scales.
A substantial effort is required to translate the outcome of 
the machine learning algorithm into useful information for 
the clinician. Most studies present a figure illustrating which 
brain areas contained the information on which the prediction 
is based alongside the usual performance metrics of 
sensitivity and specificity. This brain map can help convince 
the clinician of the robustness of the predictions, particularly 
if the areas highlighted have been independently linked to 
the outcome by other reports. For instance, our work using 
structural MRI to predict treatment response in depression 
confirms the well-replicated link between anterior cingulate 
and AD response.40,60 New insights into the mechanisms of 
brain disorders will also likely be revealed. Machine learning 
prediction, in common with other multivariate, pattern-based 
approaches, is also more sensitive to distributed patterns 
of changes that are too weak to survive the strict multiple 
comparison correction of usual mass-univariate approaches, 
as in conventional analysis. Increased sensitivity may account 
for the more complex patterns of abnormalities that machine 
learning studies generally reveal relative to conventional 
group analysis.36,48,83
The ethical, social, and clinical arguments for the 
development of biomarkers for diagnosis and prognosis in 
psychiatry are clear and imperative. It is foreseeable that the 
clinical assessment for some psychiatric disorders will soon 
include a brain imaging scan. In fact, the addition of these 
new analysis techniques to the usual diagnostic work up for 
dementia is likely to be the first application of neuroimaging-
based prediction implemented in clinical practice.
In summary, neuroimaging research has revealed that 
psychiatric disorders are associated with complex, 
distributed, multimodal patterns of brain abnormalities. We 
have discussed how machine learning can provide a unique 
link between in vivo brain measurements of individual 
patients and their symptoms, behaviours, and clinical 
outcomes. This innovation opens the way for the translation 
of neuroimaging findings into clinical tools for psychiatry 
and has the potential to make a significant contribution to 
psychiatric classification by identifying the neurobiology in 
an iterative process.
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